European regulators to review GSK's asthma drug Nucala to treat COPD
The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
Zacks Investment Research on MSN7d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...
Fierce Pharma6d
GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
GSK application to expand use of Nucala to COPD accepted for review by EMA
GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...
Yahoo Finance6d
EMA to review GSK’s Nucala for COPD treatment expansion
The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary ...
Healio4d
Mepolizumab lowers repeat surgery risk for CRSwNP regardless of number of past surgeries
Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...
EMA accepts GSK's application to expand Nucala use
GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...
Devdiscourse7d
Health Turmoil: Rising TB, Strategic Drug Reviews, and Food Safety Shifts
A 10% surge in child TB infections in Europe has prompted urgent WHO action, European regulators are evaluating GSK's drug ...
Reuters7d
European regulators to review GSK's asthma drug Nucala to treat COPD
The European Medicines Agency will review GSK's (GSK.L), opens new tab request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD ...
Nasdaq7d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab).